Format

Send to

Choose Destination
Arthritis Rheumatol. 2017 Apr;69(4):837-845. doi: 10.1002/art.40044. Epub 2017 Mar 3.

A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.

Author information

1
Cleveland Clinic, Cleveland, Ohio.
2
University of South Florida, Tampa.
3
Mayo Clinic, Rochester, Minnesota.
4
St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada.
5
Boston University, Boston, Massachusetts.
6
Mount Sinai Hospital, Toronto, Ontario, Canada.
7
Johns Hopkins University, Baltimore, Maryland.
8
University of Pittsburgh, Pittsburgh, Pennsylvania.
9
Cedars-Sinai Medical Center, Los Angeles, California.
10
University of Utah, Salt Lake City.
11
University of Pennsylvania, Philadelphia.
12
Hospital for Special Surgery, New York, New York.

Abstract

OBJECTIVE:

To compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA).

METHODS:

In this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double-blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse-free survival rate).

RESULTS:

Forty-nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; of these, 41 reached the week 12 randomization and underwent a blinded randomization to receive abatacept or placebo. Prednisone was tapered using a standardized schedule, reaching a daily dosage of 20 mg at week 12 with discontinuation in all patients at week 28. The relapse-free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (P = 0.049). A longer median duration of remission was seen in those receiving abatacept compared to those receiving placebo (median duration 9.9 months versus 3.9 months; P = 0.023). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms.

CONCLUSION:

In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00556439.

PMID:
28133925
PMCID:
PMC5378642
DOI:
10.1002/art.40044
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center